Wir sind mit live! Mehr erfahren

Vertex Pharmaceuticals

VRTX

Börsenwert 127 Mrd. $

499,74 USD

-9,01

1,77 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

502,00

+2,26

0,45 %

1 Tag

-1,77 %

5 Tage

-2,48 %

1 Monat

-2,63 %

3 Monate

2,82 %

6 Monate

14,71 %

Seit Jahresbeginn

10,53 %

1 Jahr

22,3 %

5 Jahre

176,4 %

10 Jahre

520,8 %

Profil: Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).

Mitarbeiter: 6.400

Gesundheitswesen Biotechnologie

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 53,4 %

Neutral 37 %

Negativ 9,6 %

Zacks Investment Research

Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?

Zacks Investment Research

Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts

Vertex Pharmaceuticals (VRTX) reached $508.75 at the closing of the latest trading day, reflecting a +2.06% change compared to its last close.

Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts

The Motley Fool

Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders

Thanks to its most recent acquisition, Vertex now has some promising products in the field of hormone disorders. These could eventually become meaningful growth drivers for the company.

Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders

The Motley Fool

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Moderna is leveraging its mRNA platform to expand beyond COVID-19 vaccines into RSV and oncology therapeutics. Vertex Pharmaceuticals maintains market dominance in cystic fibrosis while successfully diversifying into gene therapy and pain management.

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism

Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines. Key Takeaways: Big pharma acquisitions are hitting record highs to combat impending patent cliffs.

Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism

Zacks Investment Research

Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $510.08, marking a +1.36% move from the previous day.

Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know

Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversib.

Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference

Vertex to Announce Third Quarter 2026 Financial Results November 2nd

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2026 financial results on Monday, November 2, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Third Quarter 2026 Earnings Call.” The conference call will be webcast live and a link to the webcast ca.

Vertex to Announce Third Quarter 2026 Financial Results November 2nd

CNBC Television

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter

Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter

Zacks Investment Research

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt